Biopsy Closure Device Market

The global biopsy closure device market is projected to total USD 0.60 billion in 2026, advancing to USD 1.48 billion by 2036, achieving a compound annual growth rate of 9.4%. Growth is driven by the escalating global volume of diagnostic and surveillance biopsy procedures, coupled with a rising imperative to minimize post-procedural complications and enhance patient recovery in both hospital and outpatient settings.

Summary of Biopsy Closure Device Market

• Market Snapshot
  • Global biopsy closure device market revenue stood at USD0.60billionin 2026 and is forecast to reach USD1.48billionby 2036.
  • At a9.4%CAGRfrom 2026 to 2036, this market is set to expand1.48xin value, adding USD0.88billionin absolute opportunity.
  • Growth is being driven by increasing procedural volumes of minimally invasive biopsies, where closure devices are essential to reduce complications such as bleeding and infection.
  • These devices are evolving into precision wound management tools, enabling faster recovery, reduced hospital stays, and improved patient outcomes.
• Demand and Growth Drivers
  • Rising incidence of cancer and chronic diseases is increasing biopsy procedure volumes globally, directly driving demand for closure devices.
  • Increasing preference for minimally invasive diagnostic procedures is reinforcing the need for efficient and reliable closure solutions.
  • Growing emphasis on post-procedure complication reduction, particularly bleeding and infection control, is accelerating adoption.
  • Expansion of ambulatory surgicalcentersand outpatient procedures is supporting demand for quick and effective closure technologies.
  • Advancements inbioabsorbablematerials and device design are improving clinical outcomes and usability.
• Product and Segment View
  • Collagen-based Plugshold4.3% of product segment share in 2026,emergingas the leading segment due to widespread use in interventional procedures.
  • Cardiovascular Biopsiesaccount for53.6% of application share in 2026, positioning this as the dominant segment driven by high procedural volumes.
  • Hospitalsrepresent72.5% of end-use share in 2026, reflecting the concentration of complex biopsy procedures in hospital settings.
  • Product categories include:
    • Vascular closure devices
    • Tissue sealants
    • Suturing systems
    • Adhesive-based closure systems
• Geography and Competitive Outlook
  • Growth is supported across North America, Europe, and Asia Pacific, driven by expanding healthcare infrastructure and diagnostic capabilities.
  • United States (12.1%CAGR),China(13.1%), Germany(10.2%),France(10.1%), Brazil(7.4%),are key growth markets.
  • Market expansion is closely tied to increasing diagnostic screening rates, healthcare access, and technological advancements in minimally invasive procedures.
  • Key companies active in this market include Abbott Laboratories, Becton Dickinson and Company, Medtronic, Terumo Corporation, and Teleflex Incorporated.

Biopsy Closure Device Market — At a Glance

As biopsy techniques become more frequent and sophisticated, the demand for reliable, rapid hemostasis has transformed closure from an ancillary concern into a critical component of procedural safety and efficiency. These devices address the significant clinical need to prevent bleeding, reduce the risk of hematoma, and potentially shorten recovery times, thereby improving the overall patient experience and streamlining workflow in busy interventional departments. The market's evolution is closely linked to the trend toward minimally invasive tissue sampling across oncology, cardiology, and other specialties, where effective closure is essential for safe same-day discharge. Innovations are increasingly focused on developing solutions that are easy to deploy, compatible with various access sites and patient anatomies, and effective even in patients on anticoagulant therapy. The shift from manual compression to dedicated mechanical or biomaterial-based closure represents a significant advancement in procedural standardization and patient care.

By Device Type, Which Technology is a Proven Hemostatic Workhorse?

Collagen-based plugs command a leading 48.3 percent share. This segment's dominance is attributed to their long-standing clinical history, proven efficacy in promoting rapid clot formation, and versatility across a wide range of biopsy depths and tissue types.

They offer a straightforward, reliable solution that interventionalists trust, particularly for percutaneous procedures in vascular-rich organs, balancing effective hemostasis with ease of use.

By Application, Which High-Risk Procedure Demands Secure Closure?

Cardiovascular biopsies represent the leading application with a 53.6 percent share. Endomyocardial biopsy, in particular, is a high-stakes procedure where bleeding into the pericardial space can be catastrophic.

This critical need for absolute hemostatic security in a high-pressure vascular environment drives the adoption and continuous refinement of dedicated closure devices, making it the most demanding and innovation-focused segment.

By End User, Where is the Highest Volume of Complex Biopsies Performed?

Hospitals constitute the primary end-user segment at 72.5 percent. Tertiary care hospitals and academic medical centers perform the vast majority of complex, deep-tissue, and high-risk biopsies that require assured closure.

The concentration of interventional radiologists, cardiologists, and oncologists, along with the management of patients with multiple comorbidities, centralizes both the need and procurement for these devices within hospital settings.

The paramount driver for this market is the global increase in image-guided biopsy procedures, fueled by rising cancer incidence and the expansion of personalized medicine requiring tissue for genomic profiling. A significant restraint is the additional per-procedure cost that closure devices add, which can hinder adoption in budget-constrained settings, leading some providers to default to longer manual compression despite its inefficiencies.

A key opportunity lies in the development of next-generation bioactive sealants that not only achieve hemostasis but also deliver antimicrobial or analgesic agents to the tract, potentially reducing infection risk and post-procedural pain.

The dominant trend is the seamless integration of closure mechanisms into single-use biopsy needle systems, creating an all-in-one "biopsy-and-close" device that streamlines the procedure, reduces inventory, and standardizes outcomes, moving closure from a separate step to an intrinsic part of the tissue sampling process.

What drives the USA's High-Volume Interventional Practice and Outpatient Shift?

The high volume of diagnostic biopsies performed annually and the strong economic and clinical push to move these procedures from inpatient to ambulatory settings propels the USA’s 12.1% CAGR. Effective closure devices are essential for enabling safe same-day discharge.

Growth is further driven by the presence of leading device innovators, favorable reimbursement for closure technologies, and rigorous hospital protocols aimed at minimizing complication-related readmissions, making these devices a standard of care in many interventional suites.

How is Brazil's Expanding Diagnostic Infrastructure Influencing Market Growth?

Brazil's 12.6% CAGR is linked to the ongoing expansion and modernization of its diagnostic imaging and oncology care infrastructure. As access to advanced biopsy techniques like core needle and vacuum-assisted biopsy increases in both public and private hospitals, so does the need for reliable post-procedural management.

Market growth is characterized by the adoption of proven, cost-effective closure solutions, particularly collagen plugs, to improve patient safety and throughput in a growing number of procedural centers.

What Strategic Healthcare Modernization Goals Underpin China's Growth?

China's leading 13.1% CAGR is driven by massive investments in upgrading its cancer diagnosis and treatment capabilities as part of broader healthcare modernization. The establishment of numerous new cancer centers and the rapid adoption of image-guided biopsy techniques create a surging demand for associated procedural tools, including closure devices. The market is also shaped by a growing domestic medical device sector actively developing and manufacturing closure products to meet local demand.

What characterizes Germany's Evidence-Based and Protocol-Driven Market?

Germany's 10.2% growth reflects a market where adoption is guided by strong clinical evidence, quality assurance protocols, and a focus on minimizing hospital stays. The well-established system of interventional radiology and day-case surgery supports steady demand for devices that enhance procedural safety and efficiency.

Procurement decisions are heavily influenced by clinical data demonstrating reductions in complication rates and by the recommendations of professional societies, favoring reliable and well-studied technologies.

What defines France's Centralized Health System's Approach to Adoption?

France's 10.1% CAGR is shaped by its centralized healthcare system's focus on standardizing care and controlling costs. The adoption of new medical devices, including biopsy closure systems, is influenced by health technology assessments that evaluate clinical benefit and cost-effectiveness.

Growth is steady, driven by the integration of approved devices into national and hospital-level procedural guidelines for biopsies, particularly in high-volume public hospitals, ensuring their use becomes part of standardized best practice.

The competitive landscape features a mix of large, diversified medtech corporations with broad interventional portfolios and smaller companies specializing in hemostasis or biopsy technologies. Competition centers on product efficacy, ease of use, and compatibility with different biopsy needles and access routes.

Success is increasingly determined by a company's ability to provide a comprehensive solution that includes not just the closure device itself, but also compatible biopsy instruments and clear, simplified deployment protocols that integrate smoothly into existing clinical workflows.

Companies compete through direct clinical support and training for interventional staff, as well as by generating robust real-world evidence that demonstrates reductions in post-procedural complications and associated costs. Strategic partnerships with biopsy needle manufacturers to create co-packaged or integrated systems are becoming a key differentiator, as they offer a streamlined value proposition to hospitals seeking to optimize procedural efficiency and patient safety.

• Cardinal Health, Inc.
• Becton, Dickinson and Company
• Merit Medical Systems, Inc.
• Terumo Corporation
• Teleflex Incorporated
• Others

• European Society of Cardiology. (2025). Guidelines on the Use of Endomyocardial Biopsy. European Heart Journal.
• National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Principles of Diagnostic Biopsy. NCCN.
• Sacks, D., & Matsumoto, A. H. (2024). Society of Interventional Radiology Position Statement on Percutaneous Image-Guided Biopsy. Journal of Vascular and Interventional Radiology.
• Swanson, N. A., & Lee, G. K. (2025). Tract Hemostasis after Percutaneous Biopsy: A Review of Current Technologies and Outcomes. Cardiovascular and Interventional Radiology.
• World Health Organization. (2025). WHO List of Priority Medical Devices for Cancer Management. WHO.

• Device Type :

  • Collagen-based Plugs
  • Sealant-based Systems
  • Suture-mediated Devices

• Application :

  • Cardiovascular Biopsies
  • Oncology Biopsies
  • Others

• End User :

  • Hospitals
  • Diagnostic Centers
  • ASCs

• Region :

  • North America

    • USA
    • Canada

  • Latin America

    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America

  • Western Europe

    • Germany
    • France
    • Italy
    • Spain
    • UK
    • BENELUX
    • Rest of Western Europe

  • Eastern Europe

    • Russia
    • Poland
    • Czech Republic
    • Rest of Eastern Europe

  • East Asia

    • China
    • Japan
    • South Korea
    • Rest of East Asia

  • South Asia & Pacific

    • India
    • ASEAN
    • Australia
    • Rest of South Asia & Pacific

  • MEA

    • GCC Countries
    • South Africa
    • Turkiye
    • Rest of MEA